Insights Into Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal.

Yusri elsayedAmbrx biopharmaGolden crossGlobal therapeutic area headJohnson innovativeInsights into johnsonPerformance versus peers in pharmaceuticalsCross on the technical charts signals